763 related articles for article (PubMed ID: 20102519)
1. Amyotrophic lateral sclerosis and frontotemporal lobar degeneration: a spectrum of TDP-43 proteinopathies.
Geser F; Lee VM; Trojanowski JQ
Neuropathology; 2010 Apr; 30(2):103-12. PubMed ID: 20102519
[TBL] [Abstract][Full Text] [Related]
2. TDP-43 is consistently co-localized with ubiquitinated inclusions in sporadic and Guam amyotrophic lateral sclerosis but not in familial amyotrophic lateral sclerosis with and without SOD1 mutations.
Maekawa S; Leigh PN; King A; Jones E; Steele JC; Bodi I; Shaw CE; Hortobagyi T; Al-Sarraj S
Neuropathology; 2009 Dec; 29(6):672-83. PubMed ID: 19496940
[TBL] [Abstract][Full Text] [Related]
3. Possible concurrence of TDP-43, tau and other proteins in amyotrophic lateral sclerosis/frontotemporal lobar degeneration.
Takeda T
Neuropathology; 2018 Feb; 38(1):72-81. PubMed ID: 28960544
[TBL] [Abstract][Full Text] [Related]
4. Distinct TDP-43 inclusion morphologies in frontotemporal lobar degeneration with and without amyotrophic lateral sclerosis.
Tan RH; Yang Y; Kim WS; Dobson-Stone C; Kwok JB; Kiernan MC; Halliday GM
Acta Neuropathol Commun; 2017 Oct; 5(1):76. PubMed ID: 29078806
[TBL] [Abstract][Full Text] [Related]
5. Intracellular dynamics of Ataxin-2 in the human brains with normal and frontotemporal lobar degeneration with TDP-43 inclusions.
Watanabe R; Higashi S; Nonaka T; Kawakami I; Oshima K; Niizato K; Akiyama H; Yoshida M; Hasegawa M; Arai T
Acta Neuropathol Commun; 2020 Oct; 8(1):176. PubMed ID: 33115537
[TBL] [Abstract][Full Text] [Related]
6. The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients.
Collins M; Riascos D; Kovalik T; An J; Krupa K; Krupa K; Hood BL; Conrads TP; Renton AE; Traynor BJ; Bowser R
Acta Neuropathol; 2012 Nov; 124(5):717-32. PubMed ID: 22993125
[TBL] [Abstract][Full Text] [Related]
7. [FTLD/ALS as TDP-43 proteinopathies].
Ishihara T; Ariizumi Y; Shiga A; Yokoseki A; Sato T; Toyoshima Y; Kakita A; Takahashi H; Nishizawa M; Onodera O
Rinsho Shinkeigaku; 2010 Nov; 50(11):1022-4. PubMed ID: 21921552
[TBL] [Abstract][Full Text] [Related]
8. Lower motor neuron involvement in TAR DNA-binding protein of 43 kDa-related frontotemporal lobar degeneration and amyotrophic lateral sclerosis.
Riku Y; Watanabe H; Yoshida M; Tatsumi S; Mimuro M; Iwasaki Y; Katsuno M; Iguchi Y; Masuda M; Senda J; Ishigaki S; Udagawa T; Sobue G
JAMA Neurol; 2014 Feb; 71(2):172-9. PubMed ID: 24378564
[TBL] [Abstract][Full Text] [Related]
9. p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS.
Al-Sarraj S; King A; Troakes C; Smith B; Maekawa S; Bodi I; Rogelj B; Al-Chalabi A; Hortobágyi T; Shaw CE
Acta Neuropathol; 2011 Dec; 122(6):691-702. PubMed ID: 22101323
[TBL] [Abstract][Full Text] [Related]
10. [Clinical and pathological spectrum of TDP-43 associated ALS].
Onodera O; Yokoseki A; Tan CF; Ishihara T; Nishiira Y; Toyoshima Y; Kakita A; Nishizawa M; Takahashi H
Rinsho Shinkeigaku; 2010 Nov; 50(11):940-2. PubMed ID: 21921519
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylated and cleaved TDP-43 in ALS, FTLD and other neurodegenerative disorders and in cellular models of TDP-43 proteinopathy.
Arai T; Hasegawa M; Nonoka T; Kametani F; Yamashita M; Hosokawa M; Niizato K; Tsuchiya K; Kobayashi Z; Ikeda K; Yoshida M; Onaya M; Fujishiro H; Akiyama H
Neuropathology; 2010 Apr; 30(2):170-81. PubMed ID: 20102522
[TBL] [Abstract][Full Text] [Related]
12. Disease animal models of TDP-43 proteinopathy and their pre-clinical applications.
Liu YC; Chiang PM; Tsai KJ
Int J Mol Sci; 2013 Oct; 14(10):20079-111. PubMed ID: 24113586
[TBL] [Abstract][Full Text] [Related]
13. Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam.
Geser F; Winton MJ; Kwong LK; Xu Y; Xie SX; Igaz LM; Garruto RM; Perl DP; Galasko D; Lee VM; Trojanowski JQ
Acta Neuropathol; 2008 Jan; 115(1):133-45. PubMed ID: 17713769
[TBL] [Abstract][Full Text] [Related]
14. Reappraisal of the anatomical spreading and propagation hypothesis about TDP-43 aggregation in amyotrophic lateral sclerosis and frontotemporal lobar degeneration.
Riku Y
Neuropathology; 2020 Oct; 40(5):426-435. PubMed ID: 32157757
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive assessment of TDP-43 neuropathology data in the National Alzheimer's Coordinating Center database.
Woodworth DC; Nguyen KM; Sordo L; Scambray KA; Head E; Kawas CH; Corrada MM; Nelson PT; Sajjadi SA
Acta Neuropathol; 2024 Jun; 147(1):103. PubMed ID: 38896163
[TBL] [Abstract][Full Text] [Related]
16. Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders.
Janssens J; Van Broeckhoven C
Hum Mol Genet; 2013 Oct; 22(R1):R77-87. PubMed ID: 23900071
[TBL] [Abstract][Full Text] [Related]
17. Molecular Mechanisms Underlying TDP-43 Pathology in Cellular and Animal Models of ALS and FTLD.
Wood A; Gurfinkel Y; Polain N; Lamont W; Lyn Rea S
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946763
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms Associated with TDP-43 Neurotoxicity in ALS/FTLD.
Shenouda M; Zhang AB; Weichert A; Robertson J
Adv Neurobiol; 2018; 20():239-263. PubMed ID: 29916022
[TBL] [Abstract][Full Text] [Related]
19. Optineurin inclusions occur in a minority of TDP-43 positive ALS and FTLD-TDP cases and are rarely observed in other neurodegenerative disorders.
Hortobágyi T; Troakes C; Nishimura AL; Vance C; van Swieten JC; Seelaar H; King A; Al-Sarraj S; Rogelj B; Shaw CE
Acta Neuropathol; 2011 Apr; 121(4):519-27. PubMed ID: 21360076
[TBL] [Abstract][Full Text] [Related]
20. Annexin A11 aggregation in FTLD-TDP type C and related neurodegenerative disease proteinopathies.
Robinson JL; Suh E; Xu Y; Hurtig HI; Elman L; McMillan CT; Irwin DJ; Porta S; Van Deerlin VM; Lee EB
Acta Neuropathol; 2024 Jun; 147(1):104. PubMed ID: 38896345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]